Sanofi

YTD

ALL

Why Robinhood?

You can watch Sanofi and buy or sell other stocks, ETFs, and their options commission-free!

About SNY

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories.

CEO

Belén Garijo López

CEOBelén Garijo López

Employees

76,493

Employees76,493

Headquarters

Paris, Ile-de-France

HeadquartersParis, Ile-de-France

Founded

1994

Founded1994

Employees

76,493

Employees76,493

SNY Key Statistics

Market cap

104.73B

Market cap104.73B

Price-Earnings ratio

17.85

Price-Earnings ratio17.85

Dividend yield

4.11%

Dividend yield4.11%

Average volume

5.33M

Average volume5.33M

High today

$42.98

High today$42.98

Low today

$41.95

Low today$41.95

Open price

$42.12

Open price$42.12

Volume

6.76M

Volume6.76M

52 Week high

$52.68

52 Week high$52.68

52 Week low

$40.89

52 Week low$40.89

SNY News

Benzinga 1d

EU Launches Antitrust Probe Into Sanofi Over Allegedly Misleading Flu Vaccine Claims

The latest action follows unannounced inspections conducted at Sanofi’s premises in September 2025. Benzinga reached out to Sanofi for comment but did not rece...

Financial Times 1d

Brussels launches antitrust probe into French drugmaker Sanofi - Financial Times

...

The Wall Street Journal 1d

Sanofi Probed by EU Over Flu Vaccine Marketing

Sanofi said it is confident that it continues to act in full compliance with all applicable laws and regulation, including competition rules. Sylvain Thomas / A...

Analyst ratings

57%

of 7 ratings

Buy

42.9%

Hold

57.1%

Sell

More SNY News

Investor's Business Daily 2d

Is Kymera Therapeutics The Next Big Rival To Regeneron And Sanofi?

Technology Is Kymera Therapeutics The Next Big Rival To Regeneron And Sanofi? Licensing Kymera Therapeutics (KYMR) shares catapulted Thursday after the company...

TipRanks 3d

Sanofi Secures Multiple June Approvals and New R&D Chief to Bolster Oncology and Neurology Push

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

TipRanks 4d

Sanofi’s RSV Study in Queensland: What Real-World Uptake Could Mean for Investors

Sanofi SA (SNY) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more co...

The Wall Street Journal 4d

Sanofi Multiple Sclerosis Drug Gets EU Approval

The U.S. Food and Drug Administration declined Sanofi’s application for multiple sclerosis drug Cenrifki in December last year. Guillaume Souvant / Agence Franc...

TipRanks 5d

MacroGenics to receive $24.5M milestone payment from Sanofi

MacroGenics (MGNX) announced that it will receive a $24.5M regulatory milestone payment from Sanofi (SNY) following the U.S. Food and Drug Administration’s acce...

TipRanks 5d

Sanofi Wins FDA Accelerated Approval for Tzield in Newly Diagnosed Stage 3 Type 1 Diabetes Children

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

TipRanks 5d

Sanofi appoints Paulo Fontoura as Global Head of R&D

Sanofi (SNY) announced the appointment of Paulo Fontoura, MD, PhD, FAAN, as Executive Vice President, Global Head of Research & Development Pharma, effective Se...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.